Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 79 points (-0.5%) at 16,635 as of Friday, Aug. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,072 issues advancing vs. 1,895 declining with 174 unchanged. The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Salix Pharmaceuticals ( SLXP), up 2.8%, and Jazz Pharmaceuticals ( JAZZ), up 2.8%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 1.1%, Abbott Laboratories ( ABT), down 1.0%, Sanofi ( SNY), down 0.8%, Novartis ( NVS), down 0.8% and GlaxoSmithKline ( GSK), down 0.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $2.25 (1.4%) to $157.85 on average volume. Thus far, 1.5 million shares of Allergan exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $156.30-$160.83 after having opened the day at $156.30 as compared to the previous trading day's close of $155.60. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $46.0 billion and is part of the health care sector. Shares are up 39.5% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 5 rate it a hold. TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Allergan Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.